JP2007530971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530971A5 JP2007530971A5 JP2007506111A JP2007506111A JP2007530971A5 JP 2007530971 A5 JP2007530971 A5 JP 2007530971A5 JP 2007506111 A JP2007506111 A JP 2007506111A JP 2007506111 A JP2007506111 A JP 2007506111A JP 2007530971 A5 JP2007530971 A5 JP 2007530971A5
- Authority
- JP
- Japan
- Prior art keywords
- exchange chromatography
- liquid
- ion exchange
- matrix
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400886A SE0400886D0 (sv) | 2004-04-02 | 2004-04-02 | Process of purification |
| SE0400886-8 | 2004-04-02 | ||
| PCT/SE2005/000467 WO2005094960A1 (en) | 2004-04-02 | 2005-03-31 | A method for chromatographic purification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530971A JP2007530971A (ja) | 2007-11-01 |
| JP2007530971A5 true JP2007530971A5 (OSRAM) | 2008-05-15 |
| JP4831697B2 JP4831697B2 (ja) | 2011-12-07 |
Family
ID=32173667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506111A Expired - Lifetime JP4831697B2 (ja) | 2004-04-02 | 2005-03-31 | 精製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070213513A1 (OSRAM) |
| EP (1) | EP1729867B1 (OSRAM) |
| JP (1) | JP4831697B2 (OSRAM) |
| AT (1) | ATE485880T1 (OSRAM) |
| AU (1) | AU2005228834A1 (OSRAM) |
| CA (1) | CA2560012A1 (OSRAM) |
| DE (1) | DE602005024373D1 (OSRAM) |
| SE (1) | SE0400886D0 (OSRAM) |
| WO (1) | WO2005094960A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| MX353340B (es) | 2006-09-13 | 2018-01-09 | Abbvie Inc | Mejoras de cultivos celulares. |
| JP2010530462A (ja) * | 2007-06-19 | 2010-09-09 | ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー | ポリマー2相システムおよびその使用 |
| AU2009204998B2 (en) | 2008-01-18 | 2014-03-27 | F. Hoffmann-La Roche Ag | Purification of non-glycosylated proteins |
| JP5596560B2 (ja) * | 2008-02-05 | 2014-09-24 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 分離媒体の製造方法 |
| FR2930780B1 (fr) * | 2008-04-30 | 2010-08-20 | Moet & Chandon | Procede de degorgement de vins mousseux |
| US20090318674A1 (en) * | 2008-06-03 | 2009-12-24 | Gagnon Peter S | Process for purification of antibodies |
| TW201024318A (en) * | 2008-10-20 | 2010-07-01 | Abbott Lab | Isolation and purification of antibodies using protein A affinity chromatography |
| SG195577A1 (en) | 2008-10-20 | 2013-12-30 | Abbott Lab | Viral inactivation during purification of antibodies |
| ES2656167T5 (es) | 2011-03-16 | 2021-03-26 | Hoffmann La Roche | Cromatografía de intercambio iónico con selectividad mejorada para la separación de monómeros, agregados y fragmentos polipeptídicos mediante la modulación de la fase móvil |
| JP6147726B2 (ja) | 2011-03-29 | 2017-06-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | タンパク質精製のためのバッファー系 |
| KR101901830B1 (ko) * | 2011-06-08 | 2018-09-27 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 제한된 공수화 크로마토그래피를 통한 생물학적 산물의 정제 |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| JPWO2015041218A1 (ja) * | 2013-09-17 | 2017-03-02 | 株式会社カネカ | 新規抗体精製方法及びそれから得られる抗体(NovelAntibodyPurificationMethodandAntibodyobtainedtherefrom)、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体(NovelAntibodyPurificationmethodusingCationExchangerandAntibodyobtainedtherefrom) |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| KR20230041834A (ko) | 2016-08-16 | 2023-03-24 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| CN119492842A (zh) | 2016-10-25 | 2025-02-21 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| CN108152104B (zh) * | 2017-12-25 | 2020-08-11 | 上海微谱化工技术服务有限公司 | 超支化水性聚氨酯中二氧化硅填料的分离及定量方法 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| WO2019237100A1 (en) * | 2018-06-08 | 2019-12-12 | Board Of Regents, The University Of Texas System | Systems and methods for separation of olefins from mixtures that contain reducing agents |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| EP3934620A1 (en) | 2019-03-05 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Human serum albumin in formulations |
| EP4038082A1 (en) * | 2019-10-04 | 2022-08-10 | Merck Patent GmbH | Elution of monoclonal antibodies in protein a affinity chromatography |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| EP0119767B1 (en) * | 1983-03-11 | 1990-11-22 | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. | Method of measuring ligands |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| DE3789413T2 (de) * | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5151358A (en) * | 1989-06-13 | 1992-09-29 | Genencor International, Inc. | Processes for the recovery of naturally produced chymosin |
| DE4321904B4 (de) * | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US5561064A (en) * | 1994-02-01 | 1996-10-01 | Vical Incorporated | Production of pharmaceutical-grade plasmid DNA |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| SE9503925D0 (sv) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separationsmedium för IgG |
| WO1998017312A1 (en) * | 1996-10-22 | 1998-04-30 | Chugai Seiyaku Kabushiki Kaisha | Sepsis remedy comprising anti-il-8 antibody as active ingredient |
| AUPR110100A0 (en) * | 2000-10-30 | 2000-11-23 | Life Therapeutics Limited | Improved separation of macromolecules |
| US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US7998705B2 (en) * | 2002-08-06 | 2011-08-16 | FUJIFILM Diosynth Biotechnologies U.S.A., Inc | Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol |
| US20060275766A1 (en) * | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
-
2004
- 2004-04-02 SE SE0400886A patent/SE0400886D0/xx unknown
-
2005
- 2005-03-31 US US10/594,187 patent/US20070213513A1/en not_active Abandoned
- 2005-03-31 AT AT05722292T patent/ATE485880T1/de not_active IP Right Cessation
- 2005-03-31 EP EP05722292A patent/EP1729867B1/en not_active Expired - Lifetime
- 2005-03-31 JP JP2007506111A patent/JP4831697B2/ja not_active Expired - Lifetime
- 2005-03-31 DE DE602005024373T patent/DE602005024373D1/de not_active Expired - Lifetime
- 2005-03-31 WO PCT/SE2005/000467 patent/WO2005094960A1/en not_active Ceased
- 2005-03-31 AU AU2005228834A patent/AU2005228834A1/en not_active Abandoned
- 2005-03-31 CA CA002560012A patent/CA2560012A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Chip-based solid-phase extraction pretreatment for direct electrospray mass spectrometry analysis using an array of monolithic columns in a polymeric substrate | |
| Sun et al. | Application of immobilized metal affinity chromatography in proteomics | |
| Kokubu et al. | Specificity of immobilized metal affinity-based IMAC/C18 tip enrichment of phosphopeptides for protein phosphorylation analysis | |
| Luo et al. | Preparation of 20-μm-id silica-based monolithic columns and their performance for proteomics analyses | |
| Ma et al. | Immobilized enzyme reactors in proteomics | |
| CN104374848B (zh) | 一种苯硼酸材料富集糖肽的方法 | |
| CN104096544A (zh) | 以氨基苯并咪唑为功能配基的层析介质及其制备方法 | |
| JP2007525501A5 (OSRAM) | ||
| CN102183603B (zh) | 一种全氟毛细管萃取整体柱及其制备方法和应用 | |
| JP2008500554A5 (OSRAM) | ||
| Aprilita et al. | Poly (glycidyl methacrylate/divinylbenzene)-IDA-FeIII in phosphoproteomics | |
| JP2006512283A5 (OSRAM) | ||
| Pluskal | Microscale sample preparation | |
| SE0400886D0 (sv) | Process of purification | |
| HRP20210849T1 (hr) | Afinitetna podloga i postupak hvatanja supstance korištenjem iste podloge | |
| SE0400490D0 (sv) | Plasmid purification | |
| Moravcová et al. | Monoliths in capillary electrochromatography and capillary liquid chromatography in conjunction with mass spectrometry | |
| Yang et al. | Amide and multihydroxyl complementary tailored metal–organic framework with enhanced glycan affinity for efficient glycoproteomic analysis | |
| Zhou et al. | Proteomic reactors and their applications in biology | |
| JP2008503754A5 (OSRAM) | ||
| Cingöz et al. | Evaluation of various immobilized enzymatic microreactors coupled on-line with liquid chromatography and mass spectrometry detection for quantitative analysis of cytochrome c | |
| Kuban et al. | Ni (II) functionalized polyhedral oligomeric silsesquioxane based capillary monolith for purification of histidine-tagged proteins by immobilized metal affinity micro-chromatography | |
| Liu et al. | Effects of spacer arm on penicillin G acylase purification using immobilized metal affinity membranes | |
| SE9904272D0 (sv) | A method for selective removal of a substance from samples containing compounds having nucleic acid structure | |
| Mess et al. | Selection of HILIC columns to handle matrix effect due to phospholipids |